DEEP RESEARCH · Sunic System (171090.KQ) · Vacuum Deposition

Sunic System: Twin Engines — Gen 8.6 OLED Cash Cow + Perovskite Tandem Inflection

Cracking Canon Tokki's Gen 8.6 monopoly created the cash cow; vacuum thermal evaporation (VTE) is becoming the de facto standard for perovskite tandem mass production — reframing the company as a "vacuum-tech platform."

Date: 2026-02-08 · Personal research note · Source: Naver blog original

0. Bottom line first

Official fact: FY25 revenue KRW 515.8bn (+356.7%), operating profit KRW 111.5bn (+1,312.5%), net income KRW 96.5bn (returned to profit). Driven by recognition of Gen 8.6 evaporators delivered to BOE B16.

Interpretation: Consensus (KRW 56–89bn OP) was decisively beaten. With perovskite pilot orders potentially added in 2026, earnings surprises could repeat.

1. Business model: a three-pillar evolution

1.1 The "vacuum evaporation" moat

• Monopoly breaker: the only credible competitor to Canon Tokki in Gen 8.6 large-area deposition — the BOE B16 win proves "indispensable alternative" status.
• Cost advantage: roughly 50–60% of Japanese rivals' price — a strong entry barrier.
• Leverage: the core ability to evaporate organics in vacuum and form atomic-scale uniform films applies equally to OLED pixels and perovskite active layers — no need to rebuild R&D to enter the energy market.

2. End market: perovskite solar revolution

2.1 From silicon to tandem

Crystalline silicon (c-Si) is up against the Shockley-Queisser limit (~29%). The industry's only answer is perovskite-silicon tandem — spectral splitting raises the theoretical limit to 43%+.

The key challenge is forming a uniform thin film over the pyramid-textured silicon — liquid pools in the valleys and misses the peaks, so vapor deposition wins.

2.2 Market size and growth (2026–2035)

Even on the conservative path (~USD 24bn), the market grows at least 30x–80x over a decade — outpacing the early-cycle growth of semis or displays.

2.3 Sunic System's SAM

• Total equipment TAM: USD 1.2bn in 2025 → USD 4.1bn by 2032 (Future Market Report).
• Assuming vacuum evaporators ~50% of equipment capex → Sunic SAM: ~USD 600m in 2025 → ~USD 2.05bn by 2032.
• With 2024 revenue ~KRW 150bn, the revenue ceiling expands by more than 10x.

3. Why Sunic wins — the process war

3.1 Catalysts: 2026 commercialization roadmap

• Hanwha Q CELLS: targets perovskite tandem mass production in 2026 — Sunic is deeply engaged in national projects and equipment development.
• Government R&D budget: 2026 solar R&D budget set at KRW 69.3bn (+47% YoY), focused on tandem.
• Price advantage: ~50% of Canon Tokki / Ulvac — attractive for Chinese and global customers.

4. Financial health and capital allocation

4.1 Turnaround completed in 2025

• Revenue KRW 515.8bn (+356.7%), OP KRW 111.5bn (+1,312.5%), NI KRW 96.5bn (back to profit).
• Drives: BOE Gen 8.6 deliveries. Position as a global major equipment supplier reaffirmed; war chest for new businesses built.

4.2 Strategic bet on the future

• Pyeongtaek Brain City plant: KRW 19bn investment, completion June 2026.
• Intent: expand Gen 8.6 OLED capacity + dedicated space for perovskite and OLEDoS. Completion timing aligns with perovskite tandem mass-production capex.
• Funding: BOE down-payments and retained earnings — capex without dilution.

4.3 2026 outlook

• Consensus: revenue KRW 541bn (+51.6%), OP KRW 89.9bn.
• Given 2025 OP already beat consensus (KRW 56–89bn) at KRW 111.5bn, 2026 likely exceeds estimates again.

5. Valuation and investment conclusion

5.1 Three pillars of re-rating

1. Monopoly-breaker premium: technological leadership that beat Canon Tokki at Gen 8.6.
2. TAM expansion: from a sub-trillion-KRW display market into the multi-trillion-KRW solar-equipment market.
3. Structural growth name: diversified portfolio (OLED IT/auto, OLEDoS XR, solar energy) offsetting cyclical exposure.

Historic PER 15–20x (typical display equipment) → potential to re-rate toward 25x+, comparable with AI / energy-transition component plays (e.g., Hanmi Semiconductor re-rated alongside HBM).

5.2 Risks

• China exposure: BOE and other Chinese customers — US-China trade-friction risk.
• Process standard competition: if solution-process problems are solved for cost reasons, SAM could shrink (though tandem physics keeps vapor ahead for the foreseeable future).
• Commercialization delay: if key players like Hanwha Q CELLS push mass-production capex past 2026.

5.3 Final view: Buy / Overweight